Sperm DNA Fragmentation Testing
SCSA, TUNEL, Comet, SCD (Halosperm)
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Laboratory-developed tests; not standardized or FDA-cleared as a single assay
Reference only. Not medical advice.
What can go wrong
The clinical risk is misuse: a borderline result can drive couples toward expensive interventions (ICSI, testicular sperm extraction for ejaculated-sperm cases, antioxidant regimens) on weak evidence. Lack of assay standardization means a result from one lab may not transfer. It is a prognostic biomarker, not a diagnosis, and a normal result does not exclude infertility.
This is something to take to a clinician. The Atlas can tell you what is known about sperm dna fragmentation testing in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Sperm DNA fragmentation (SDF) testing measures breaks in sperm chromatin using assays such as SCSA (DNA Fragmentation Index), TUNEL, the Comet assay, and the sperm chromatin dispersion (SCD/Halosperm) test. High fragmentation is associated with reduced natural and IUI conception, recurrent pregnancy loss, and possibly poorer IVF outcomes. The controversy is whether routine testing changes management enough to justify its cost - guidelines are cautious, yet many clinics market it aggressively.
A real biomarker, a contested clinical use, and a popular upsell.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
SCSA uses acridine orange flow cytometry to quantify denaturable (fragmented) DNA as a DNA Fragmentation Index. TUNEL labels free DNA strand ends enzymatically. The Comet assay electrophoreses individual sperm so fragmented DNA migrates into a tail. SCD swells nuclei to reveal halos absent in fragmented sperm. The assays correlate imperfectly with each other because they probe different damage mechanisms, which is part of why thresholds are not universal.
What people get wrong
Often saidA normal DNA fragmentation result means your sperm are fine
ActuallySDF captures one axis of sperm quality. Normal DFI coexists with infertility from other causes; the test is adjunctive, not definitive.
Often saidHigh fragmentation always requires ICSI with testicular sperm
ActuallySome clinics upsell testicular sperm extraction for high ejaculated-sperm SDF, but evidence for routine TESE-ICSI in this setting is limited and the procedure is invasive.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Don Evenson pioneered the Sperm Chromatin Structure Assay in the early 1980s, repurposing flow cytometry and acridine orange to quantify chromatin abnormality. TUNEL, Comet, and SCD followed, each adding a different lens on sperm DNA integrity. Commercial uptake outpaced consensus on when results should change care.
Set against the alternatives
SCSA is the most standardized and widely published; TUNEL is sensitive but lab-dependent; Comet is research-grade and labor-intensive; SCD/Halosperm is cheap and microscope-based but coarser. None is a validated universal cutoff, and head-to-head agreement is moderate at best.
What we do not know
- Will a standardized assay and validated threshold ever achieve guideline endorsement for routine use?
- Does treating high SDF (antioxidants, varicocele repair, shorter abstinence, testicular sperm) actually improve live birth?
- How much of current SDF testing volume is evidence-driven versus revenue-driven?
At a glance
- SCSA threshold often cited
- DFI >25-30% considered elevated
- Assays measure different things
- strand breaks vs chromatin packaging vs oxidative damage
- AUA/ASRM 2024 stance
- SDF testing not recommended for routine male infertility evaluation
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Sperm DNA Fragmentation Testing. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Evenson et al. - SCSA development1980s-2000s
Established DFI as a flow-cytometry biomarker linked to fertility outcomes
Meta-analyses on SDF and pregnancy loss2010s
Associated higher SDF with increased recurrent miscarriage and reduced natural/IUI conception
AUA/ASRM Male Infertility Guideline2020/2024
Recommended against routine SDF testing in the general infertility evaluation; limited select-use cases